Characterization of TRKA Signaling in Acute Myeloid Leukemia

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Jul 27

PMID 30046390

Citations 7

Authors

Shelley M Herbrich

Sankaranarayanan Kannan

Riitta M Nolo

Marisa Hornbaker

Joya Chandra

Patrick A Zweidler-McKay

Affiliations

Soon will be listed here.

Abstract

Tropomyosin-related kinase A (TRKA) translocations have oncogenic potential and have been found in rare cases of solid tumors. Accumulating evidence indicates that TRKA and its ligand, nerve growth factor (NGF), may play a role in normal hematopoiesis and may be deregulated in leukemogenesis. Here, we report a comprehensive evaluation of TRKA signaling in normal and leukemic cells. TRKA expression is highest in common myeloid progenitors and is overexpressed in core binding factor and megakaryocytic leukemias, especially Down syndrome-related AML. Importantly, NGF can rescue GM-CSF dependent TF-1 AML cells, but does not drive proliferation in other TRKA-expressing lines. Although TRKA expression is heterogeneous between and within AML samples, NGF stimulation broadly induces ERK signaling, demonstrating the functional ability of AML cells to respond to NGF/TRKA signaling. However, neither shRNA knockdown nor pharmacologic inhibition have significant anti-proliferative effects on human AML cells and . Thus, despite functional NGF/TRKA signaling, the importance of TRKA in AML remains unclear.

Citing Articles

Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes.

Yao C, Lin C, Wang Y, Kao C, Tsai C, Hou H Blood Adv. 2024; 8(10):2442-2454.

PMID: 38527292 PMC: 11112608. DOI: 10.1182/bloodadvances.2023011512.

Nerve Growth Factor and the Role of Inflammation in Tumor Development.

Ferraguti G, Terracina S, Tarani L, Fanfarillo F, Allushi S, Caronti B Curr Issues Mol Biol. 2024; 46(2):965-989.

PMID: 38392180 PMC: 10888178. DOI: 10.3390/cimb46020062.

Systemic Optimization of Gene Electrotransfer Protocol Using Hard-to-Transfect UT-7 Cell Line as a Model.

Vadeikiene R, Jakstys B, Ugenskiene R, Satkauskas S, Juozaityte E Biomedicines. 2022; 10(11).

PMID: 36359207 PMC: 9687892. DOI: 10.3390/biomedicines10112687.

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.

Joshi S, Qian K, Bisson W, Watanabe-Smith K, Huang A, Bottomly D Blood. 2020; 135(24):2159-2170.

PMID: 32315394 PMC: 7290093. DOI: 10.1182/blood.2019003691.

Two Receptors, Two Isoforms, Two Cancers: Comprehensive Analysis of KIT and TrkA Expression in Neuroblastoma and Acute Myeloid Leukemia.

Lebedev T, Vagapova E, Popenko V, Leonova O, Spirin P, Prassolov V Front Oncol. 2019; 9:1046.

PMID: 31681584 PMC: 6813278. DOI: 10.3389/fonc.2019.01046.

References

Kralik J, Kranewitter W, Boesmueller H, Marschon R, Tschurtschenthaler G, Rumpold H . Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol. 2011; 6:19. PMC: 3063188. DOI: 10.1186/1746-1596-6-19. View

Koizumi H, Morita M, Mikami S, Shibayama E, Uchikoshi T . Immunohistochemical analysis of TrkA neurotrophin receptor expression in human non-neuronal carcinomas. Pathol Int. 1998; 48(2):93-101. DOI: 10.1111/j.1440-1827.1998.tb03877.x. View

Grimes M, Zhou J, Beattie E, Yuen E, Hall D, Valletta J . Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes. J Neurosci. 1996; 16(24):7950-64. PMC: 6579208. View

Xie P, Cheung W, Ip F, Ip N, Leung M . Induction of TrkA receptor by retinoic acid in leukaemia cell lines. Neuroreport. 1997; 8(5):1067-70. DOI: 10.1097/00001756-199703240-00001. View

Ardini E, Bosotti R, Borgia A, De Ponti C, Somaschini A, Cammarota R . The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014; 8(8):1495-507. PMC: 5528583. DOI: 10.1016/j.molonc.2014.06.001. View

Kaebisch A, Brokt S, Seay U, Lohmeyer J, Jaeger U, Pralle H . Expression of the nerve growth factor receptor c-TRK in human myeloid leukaemia cells. Br J Haematol. 1996; 95(1):102-9. DOI: 10.1046/j.1365-2141.1996.d01-1874.x. View

Auffray I, Chevalier S, Froger J, Izac B, Vainchenker W, Gascan H . Nerve growth factor is involved in the supportive effect by bone marrow--derived stromal cells of the factor-dependent human cell line UT-7. Blood. 1996; 88(5):1608-18. View

Mulloy J, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O . AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci U S A. 2005; 102(11):4016-21. PMC: 554792. DOI: 10.1073/pnas.0404701102. View

Li Z, Beutel G, Rhein M, Meyer J, Koenecke C, Neumann T . High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood. 2008; 113(9):2028-37. PMC: 2651014. DOI: 10.1182/blood-2008-05-155200. View

10.

Ehrhard P, Ganter U, Stalder A, Bauer J, Otten U . Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci U S A. 1993; 90(12):5423-7. PMC: 46732. DOI: 10.1073/pnas.90.12.5423. View

11.

Watson F, Porcionatto M, Bhattacharyya A, Stiles C, Segal R . TrkA glycosylation regulates receptor localization and activity. J Neurobiol. 1999; 39(2):323-36. DOI: 10.1002/(sici)1097-4695(199905)39:2<323::aid-neu15>3.0.co;2-4. View

12.

Chevalier S, Praloran V, Smith C, MacGrogan D, Ip N, Yancopoulos G . Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells. Blood. 1994; 83(6):1479-85. View

13.

De Kouchkovsky I, Abdul-Hay M . 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016; 6(7):e441. PMC: 5030376. DOI: 10.1038/bcj.2016.50. View

14.

Mitra G, Long L, Barbacid M . Molecular characterization of the human trk oncogene. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 2:983-92. DOI: 10.1101/sqb.1986.051.01.112. View

15.

Vaishnavi A, Capelletti M, Le A, Kako S, Butaney M, Ercan D . Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013; 19(11):1469-1472. PMC: 3823836. DOI: 10.1038/nm.3352. View

16.

Hughes S, Barbacid M . A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986; 319(6056):743-8. DOI: 10.1038/319743a0. View

17.

Descamps S, Pawlowski V, Revillion F, Hornez L, Hebbar M, Boilly B . Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res. 2001; 61(11):4337-40. View

18.

Calissano P, Cattaneo A, Biocca S, Aloe L, Mercanti D, Levi-Montalcini R . The nerve growth factor. Established findings and controversial aspects. Exp Cell Res. 1984; 154(1):1-9. DOI: 10.1016/0014-4827(84)90663-3. View

19.

Jullien J, Guili V, Reichardt L, Rudkin B . Molecular kinetics of nerve growth factor receptor trafficking and activation. J Biol Chem. 2002; 277(41):38700-8. PMC: 2693056. DOI: 10.1074/jbc.M202348200. View

20.

Davis S, Meltzer P . GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007; 23(14):1846-7. DOI: 10.1093/bioinformatics/btm254. View